Drug Profile
Research programme: CNS disorders therapeutics - Genmab/Lundbeck
Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Genmab; Lundbeck A/S
- Developer Genmab
- Class Antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in CNS-disorders in Denmark (Parenteral)
- 06 Dec 2013 Preclinical trials in CNS disorders in Denmark (Parenteral)
- 15 Dec 2011 Early research is ongoing in Denmark